Clinical Trials

BreastGastrointestinalHead & NeckThoracic

329 enrolled 23 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT06604858 2026-04-07

TELESCOPE

31 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT03546686 2026-03-27

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

51 enrolled

Breast Neoplasms

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

83 enrolled

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06797635 2026-03-13

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

372 enrolled

Breast Neoplasms

NCT01174121 2026-03-04

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

BreastGastrointestinalGynecologic

332 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

47 enrolled 17 charts

Breast Neoplasms

NCT06976944 2026-02-23

PRELUDE

44 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07188246 2026-02-11

BRINK

40 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03025035 2026-02-06

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

14 enrolled 8 charts

Breast Neoplasms

NCT03804944 2026-01-28

CBCV

100 enrolled

Breast Neoplasms

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

110 enrolled 26 charts

Breast Neoplasms

NCT05203445 2026-01-12

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

23 enrolled

Breast Neoplasms

NCT03393845 2026-01-02

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

47 enrolled

Breast Neoplasms

NCT03225547 2025-12-23

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

24 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03095352 2025-12-22

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

76 enrolled 14 charts

Breast Neoplasms

NCT04373031 2025-12-02

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

12 enrolled 11 charts

Breast Neoplasms

NCT06078384 2025-11-17

ETNA

354 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05675579 2025-11-04

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

27 enrolled

Breast Neoplasms

NCT05645380 2025-10-07

NeoTRACT

139 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02957968 2025-08-28

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491226 2025-08-27

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

35 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07015853 2025-08-27

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02755272 2025-07-04

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

87 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03747120 2025-06-27

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

138 enrolled 14 charts

Breast Neoplasms

NCT04789096 2025-06-06

TUGETHER

31 enrolled

Breast Neoplasms

NCT03222856 2025-06-05

KELLY

44 enrolled 17 charts

Breast Neoplasms

NCT04251169 2025-06-03

TATEN

20 enrolled 19 charts

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

52 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

BreastClassical hematology

23 enrolled

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03632941 2025-03-12

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

8 enrolled 13 charts

Breast Neoplasms, Neoplasms

NCT05020860 2025-02-27

RESPONSE

185 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04990921 2025-02-20

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

15 enrolled

Breast Neoplasms

NCT02752685 2025-01-29

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

70 enrolled 7 charts

Breast Neoplasms

NCT03971045 2024-11-19

PERICLES

46 enrolled

Breast Neoplasms

NCT06472583 2024-06-25

BREAST-BOOSTER

78 enrolled

Breast Neoplasms

NCT05163223 2024-06-17

Cornerstone001

10 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06407310 2024-05-09

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

25 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05033756 2024-05-07

COMPRENDO

11 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06371807 2024-04-17

KEYPARTNER

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03639948 2024-04-11

NeoPACT

120 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03841747 2024-03-12

PELICAN

Phase 2 Withdrawn